Bavarian Nordic (OTCMKTS:BVNRY) Releases Earnings Results

Bavarian Nordic (OTCMKTS:BVNRY) posted its quarterly earnings results on Thursday. The company reported ($0.20) EPS for the quarter, Zacks reports. Bavarian Nordic had a net margin of 22.20% and a return on equity of 11.44%. The company had revenue of $226.16 million for the quarter.

Bavarian Nordic Trading Up 1.3%

Shares of OTCMKTS:BVNRY opened at $9.22 on Friday. The firm has a market cap of $2.19 billion, a price-to-earnings ratio of 10.48 and a beta of 1.34. Bavarian Nordic has a 1 year low of $6.60 and a 1 year high of $13.00. The business has a fifty day simple moving average of $10.13 and a 200 day simple moving average of $10.74.

Key Headlines Impacting Bavarian Nordic

Here are the key news stories impacting Bavarian Nordic this week:

• Positive Sentiment: Agreement with Serum Institute of India (SII) to produce the chikungunya vaccine — expands manufacturing capacity and helps de‑risk supply scaling if the vaccine is approved, supporting future revenue potential. Bavarian Nordic and SII sign agreement for chikungunya vaccine production
• Positive Sentiment: Phase 3b chikungunya trial setup cited as a new catalyst — a successful late‑stage study would materially increase the commercial value of the chikungunya program and could drive upside beyond current expectations. Bavarian Nordic’s Phase 3b Chikungunya Vaccine Trial Sets Up a New Catalyst for BVNRY Investors
• Positive Sentiment: Launch of next tranche of share buy‑back program — reduces share count and is a near‑term support for the stock, signaling management confidence in cash generation. Bavarian Nordic Launches Next Tranche of Share Buy-Back Program
• Neutral Sentiment: Q4 earnings call highlighted strong financial performance (solid revenue of $226.2M, healthy margins and ROE) but with an EPS loss; investors will focus on guidance and commercialization timelines for vaccine programs. Bavarian Nordic AS (BVNKF) Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Full earnings call transcript and annual report published — useful for investors wanting detail on revenue mix, margins, and program timelines but unlikely to move the stock alone. Earnings Call Transcript Annual Report 2025
• Neutral Sentiment: Report of transactions by managerial personnel was filed — insider activity can be informative but the impact depends on whether trades were buys or sells (details in the filing). Report of transactions of shares and related securities
• Negative Sentiment: Reported EPS of ($0.20) for the quarter is a near‑term negative datapoint; until growth from commercial programs and R&D milestones begins to offset operating costs, earnings pressure could weigh on valuation. BVNRY summary/earnings

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.